 |
|
|
| |
Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Judith Aberg,1 Bronagh Shepherd,2 Marcia Wang,3 Jose V. Madruga,4 Fernando Mendo Urbina,5 Christine Katlama,6 Shannon Schrader,7 Joseph J. Eron,8 Shiven Chabria,9 Andrew Clark,10 Amy Pierce,11 Max Lataillade,9 Peter Ackerman9*
1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2GSK, Brentford, UK; 3GSK, Upper Providence, PA, USA; 4CRT-DST/AIDS SP, São Paulo, Brazil; 5Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; 6AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, INSERM-Sorbonne Universités, Paris, France; 7Schrader Clinic, Houston, TX, USA; 8University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; 9ViiV Healthcare, Branford, CT, USA; 10ViiV Healthcare, Brentford, UK; 11ViiV Healthcare, Durham, NC, USA
*Employee of ViiV Healthcare at the time of the study.
|
| |
|
|
|
|
|
